Pfizer Shopping For Deals That Will Add $25bn To 2030 Revenues
With cash to spend and a patent cliff to overcome starting in 2025, Pfizer is expected to be a prolific deal-maker in 2022.
You may also be interested in...
Worldwide President of R&D Mikael Dolsten talked to Scrip about Pfizer's busy business development track record and the company's ambition to maintain its leadership in breast cancer.
Detailed data presented at Digestive Disease Week show competitive efficacy in ulcerative colitis and a potential best-in-class safety profile for the S1P receptor modulator Pfizer acquired earlier this year.
Pfizer, Merck, Eli Lilly and Gilead all benefited from the sale of vaccines and treatments for COVID-19, but the long-term growth prospects remain uncertain, and more so for some than others.